Pfizer Corporation

Navitor Pharmaceuticals, Inc.

Janssen Pharmaceutica Nv

Raze Therapeutics, Inc.

Wyeth

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Eddine Saiah

David John O'Neill

Christoph Wolfgang Zapf

Seungil Han

Betsy Susan Pierce

Christoph Martin Dehnhardt

Joseph Walter Strohbach

David Hepworth

Nikolaos Papaioannou

Arthur Lee

Frank Eldridge Lovering

Stephen Wayne Wright

Katherine Lin Lee

John David Trzupek

Lori Krim Gavrin

John Paul Mathias

Zhao-Kui Wan

Akshay Patny

Li Huang Xing

Kevin Joseph Curran

Xiaolun Wang

Joel A Goldberg

Michael Dennis Lowe

Richard Vargas

Sridhar Narayan

David R Anderson

Mark Edward Bunnage

Horng-Chih Huang

Shomit Sengupta

Seong Woo Anthony Kang

Kristina Michelle Fetalvero

Ariamala Gopalsamy

Ivan Viktorovich Efremov

John Isidro Trujillo

Liying Zhang

Brian Stephen Gerstenberger

Andrew Fensome

Jean-Baptiste Telliez

Heather Tye

George Vlasuk

Balekudru Devadas

Margaret Lanahan Grapperhaus

Nello Mainolfi

Susan Landis Hockerman

Shaun Raj Selness

Mark E Schnute

Robert Owen Hughes

Daniel Patrick Walker

Dafydd Rhys Owen

Cristina Lecci

Jonathan Bentley

John Robert Springer

Michelle Ann Schmidt

Christophe Philippe Allais

Mikel P Moyer

Andrew Brearley

Robert David Matthew Pace

Julia Vile

Danny James Garland

John Michael McCall

Wei Li

Douglas Wilson

Tarek Suhayl Mansour

Jinbo Lee

Hairuo Peng

Lihren Chen

Kai Peter Johnsson

John C McKew

Steve Yikkai Tam

Mark Joseph Tebbe

Jason Shaoyun Xiang

Holly Atton

Mark Peter Ridgill

Mirco Meniconi

Adrian Kotey

Mark Anthony Kerry

Eva Deanna Binnun

Joel Adam Goldberg

Huan-Qiu Li

Jianchang Li

Craig Avery

Steven Mark Bromidge

Nathaniel J Monck

Katarzyna Irena Gorska

Adrian Kotei Kotey

Manus Ipek

Sarah Mahoney

Vipin Suri

Yuchuan Wu

Lisa Molz

Mark Edward Schnute

David Randolph Anderson

Mark Kerry

The present invention provides compounds, compositions thereof, and methods of using the same.

Modulators of Sestrin-GATOR2 interaction and uses thereof

Modulators of sestrin-GATOR2 interaction and uses thereof

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

Bicyclic-fused heteroaryl or aryl compounds

Caffeine inhibitors of MTHFD2 and uses thereof

Rapamycin analogs and uses thereof

The present invention provides compounds of formula I, compositions thereof, and methods of using the same as mTORC1 inhibitors.

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

The present invention provides compounds of general Formula I and I':  compositions thereof, and methods of using same to treat Rheb-mediated disorders.

Heteroaryl Rheb inhibitors and uses thereof

A compound compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C-Calkyl, C-Calkoxy, C-Ccycloalkyl, aryl, heteroaryl, aryl(C-Calkyl), CN, amino, alkylamino, dialkylamino, CF, or hydroxyl; A is selected from the group consisting of a bond, C&#x2550;O, &#x2014;SO&#x2014;, &#x2014;(C&#x2550;O)NR&#x2014;, and &#x2014;(CRR)&#x2014;, where Ris H or C-Calkyl, and Rand Rare independently hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, aryl, aryl(C-Calkyl), heteroaryl, (C-Calkyl)heteroaryl, etc.; A' is selected from the group consisting of a bond, C&#x2550;O, &#x2014;SO&#x2014;, &#x2014;(C&#x2550;O)NR&#x2032;, &#x2014;NR&#x2032;(C&#x2550;O)&#x2014;, and &#x2014;(CR&#x2032;R&#x2032;)&#x2014;, where R&#x2032; is H or C-Calkyl, and R&#x2032; and R&#x2032; are independently hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, aryl, aryl(C-Calkyl), heteroaryl, (C-Calkyl)heteroaryl, heteroaryl(C-Calkyl), and heterocyclic(C-Calkyl); Z is &#x2014;(CH)&#x2014; or a bond, where one or more methylene units are optionally substituted by one or more C-Calkyl, CN, OH, methoxy, or halo, and where said alkyl may be substituted by one or more fluorine atoms; Rand R&#x2032; are independently selected from the group consisting of hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, aryl, heteroaryl, aryl(C-Calkyl), CN, etc., wherein said alkyl, aryl, cycloalkyl, heterocyclic, or heteroaryl is further optionally substituted with one or more substituents selected from the group consisting of C-Calkyl, halo, CN, C-Calkylamino, C-Ccycloalkyl, etc.; Ris selected from the group consisting of hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, halo, and cyano, where said alkyl may be substituted by one or more fluorine atoms; Ris selected from the group consisting of hydrogen, deuterium, and amino; Ris monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl wherein said aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of C-Calkyl, heterocycloalkyl, halo, C-Ccycloalkyl, etc., where said alkyl, cycloalkyl, alkoxy, or heterocycloalkyl may be substituted by one or more C-Calkyl, halo, CN, OH, alkoxy, amino, &#x2014;COH, &#x2014;(CO)NH, &#x2014;(CO)NH(C-Calkyl), or &#x2014;(CO)N(C-Calkyl), and where said alkyl may be further substituted by one or more fluorine atoms; Ris independently selected from the group consisting of hydrogen, C-Calkyl, C-Calkoxy, and hydroxyl; h is 1, 2 or 3; j and k are independently 0, 1, 2, or 3; m and n are independently 0, 1 or 2; and, q is 0, 1 or 2. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.

Aminopyrimidinyl compounds

A compound having the structure: or an acceptable salt thereof, wherein X is N or CR, where R is hydrogen, alkyl, etc.; A is selected from the group consisting of a bond, C&#x2550;O, &#x2014;SO&#x2014;, etc.; A' is selected from the group consisting of a bond, C&#x2550;O, etc.; Z is &#x2014;(CH)&#x2014; or a bond, etc.; Rand Rare independently selected from the group consisting of hydrogen, alkyl, etc.; Ris selected from hydrogen, alkyl, etc.; Ris selected from the group consisting of hydrogen, and amino; Ris monocyclic or bicyclic, etc.; Ris independently selected from hydrogen, alkyl, etc.; h, j, k, m, n and q are integers as defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.

Growing community of inventors

Brookline, MA, United States of America

Eddine Saiah